{"url_path":"/sec/aktx/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1541157/0001493152-26-024446-index.html","accession_number":"0001493152-26-024446","cik":"0001541157","ticker":"AKTX","issuer_name":"Akari Therapeutics Plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1541157/0001493152-26-024446-index.html","primary_entity_key":"0001541157","primary_entity_name":"Akari Therapeutics Plc"},"word_count":65,"has_tables":true,"body_markdown":"**Item\n5. Other Information.**\n\n** **\n\nNone\nof our directors or “officers,” as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, adopted, modified\nor terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Item\n408(c) of Regulation S-K, which are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), during the fiscal quarter\ncovered by this report."}